Intrapleural mitoxantrone for the palliative treatment of malignant pleural effusions
Pleural effusions are common in patients with cancer and cause a significant morbidity. The optimal treatment for the control of pleural effusions is not defined. In patients with drug-sensitive tumors (e.g. breast cancer, lymphomas, small-cell lung cancer) systemic chemotherapy is the treatment of...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 1995 |
| País: | España |
| Institución: | Universidad de La Laguna (ULL) |
| Repositorio: | RIULL. Repositorio Institucional de la Universidad de La Laguna |
| OAI Identifier: | oai:riull.ull.es:915/40030 |
| Acceso en línea: | http://riull.ull.es/xmlui/handle/915/40030 |
| Access Level: | acceso abierto |
| Palabra clave: | Intrapleural mitoxantrone pleural effusions |
| Sumario: | Pleural effusions are common in patients with cancer and cause a significant morbidity. The optimal treatment for the control of pleural effusions is not defined. In patients with drug-sensitive tumors (e.g. breast cancer, lymphomas, small-cell lung cancer) systemic chemotherapy is the treatment of choice. For patients with other solid tumors and in recurrences despite systemic chemotherapy, the optimal treatment consists of thoracostomy-tube drainage with the instillation of a sclerosing agent [3]. Several agents are used to achieve pleuorodesis: tetracycline, bleomycin, quinacrine, nitrogen mustard, doxorubicin, mitoxantrone and talc [7]. Mitoxantrone shows a steep dose/effect relationship for different human tumor cell lines in vitro, and is a drug well tolerated locally [2]. Whilst the usual dose of mitoxantrone for intrapleural therapy is 30 mg [6], we increased the dose to 40 mg. |
|---|